<p>Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis</p>-Reference-Cited by-同舟云学术

Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis

Published:2020-07 Issue: Volume:Volume 12 Page:6641-6653
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Zhang Xin,Huang Hejing,Wei Ziran,Zhu Zhenxin,Yang Dejun,Fu Hongbing,Xu Jiapeng,Hu Zunqi,Zhang Yu,You Qing,Huang Xin,Yan Ronglin,Wang Weimin,Cai Qingping^ORCID

Publisher

Informa UK Limited

Subject

Oncology

Reference54 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. The long-term population impact of endoscopic screening programmes on disease burdens of gastric cancer in China: A mathematical modelling study

3. Carcinogenesis, prevention and early detection of gastric cancer: Where we are and where we should go

4. Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review

5. Cancer statistics in China, 2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of neoadjuvant chemotherapy on the clinical efficacy and serum tumor marker levels in patients undergoing radical surgery for gastric cancer;Medicine;2024-01-12

2. Lokal ileri mide kanserlerinde en-blok multiorgan rezeksiyonu yapılan hastaların erken ve geç dönem sonuçları ve bu sonuçlara etki eden faktörler;Akademik Gastroenteroloji Dergisi;2023-08-31

3. Evolution of drug therapy in patients with resectable gastric and esophageal‑gastric junction cancer;Research and Practical Medicine Journal;2023-06-09

4. Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer;Journal of Gastric Cancer;2023

5. Efficacy and safety evaluation of PSOX, DOF and SOX regimens as neoadjuvant chemotherapy for advanced gastric cancer;Future Oncology;2022-12